J&J’s stel­lar prostate can­cer da­ta sig­nals the like­li­hood of a broad­er mar­ket ap­proval, as Pfiz­er ri­val strug­gles

CHICA­GO — J&J will be look­ing to ex­pand its block­buster mar­ket for Zyti­ga (abi­raterone) af­ter post­ing stel­lar da­ta at AS­CO show­ing that the drug com­bined with stan­dard hor­mone ther­a­py reg­is­tered a ma­jor im­prove­ment in pro­gres­sion-free sur­vival among new­ly di­ag­nosed pa­tients with metasta­t­ic prostate can­cer.

The LAT­I­TUDE study da­ta demon­strat­ed that the com­bi­na­tion ther­a­py de­liv­ered an av­er­age stretch of 33 months with­out the dis­ease wors­en­ing, com­pared to 14.8 months for stan­dard hor­mone ther­a­py. Zyti­ga plus pred­nisone in com­bi­na­tion with ADT de­creased the risk of pro­gres­sion or death by 53% com­pared to place­bo plus ADT in pa­tients with mH­N­PC. And while over­all sur­vival was not reached yet for the Zyti­ga com­bo, the com­par­i­son arm came in at 34.7 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER